SPDR® MSCI Europe Health Care UCITS ETF GBP is a equity ETF from SPDR tracking the MSCI Europe Health Care index through physical replication. Domiciled in Ireland and launched in 2014, the fund manages about 595 M € and charges a TER of 0.18% — 18 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
SPDR® MSCI Europe Health Care UCITS ETF GBP competes with 261 other products in the same class and region (Equity, Europe): it ranks 69th by fund size and 56th by ongoing cost, with a TER of 0.18% against a group median of 0.25%. It has been listed since 2014, 12 years of track record.
On a €10,000 investment the TER costs 18 € a year, against 25 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 76.7% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in GBP. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Ireland, which determines the tax treatment of income received by the fund and the supervisory authority.
| Roche Holding AG | 15.5% |
| Novartis AG | 15.4% |
| AstraZeneca PLC | 15.2% |
| Novo Nordisk A/S | 8.3% |
| GSK plc | 5.7% |
| Sanofi SA | 5.0% |
| Argen-X | 3.1% |
| EssilorLuxottica S. A. | 3.0% |
| Bayer AG NA | 2.9% |
| Lonza Group AG | 2.6% |
| Borsa Italiana | STWX | EUR |
| XETRA | SPYH | EUR |
| Francoforte | SPYH | EUR |
| London Stock Exchange | HLTH | EUR |
| London Stock Exchange | HEAE | GBP |
| Euronext Paris | STW | EUR |
| SIX Swiss Exchange | STWX | CHF |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.